USPTO serial 97356365
SOCIOMICS
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- MAHONEY, KATHERINE AILEEN
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with SOCIOMICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Roger H. Bora
Roger H. Bora THOMPSON HINE LLPAUSTIN LANDING, DISCOVERY PLACE BLDG.10050 INNOVATION DRIVE, SUITE 400DAYTON, OH 45342Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Scientific and technological services in the field of pharmaceuticals featuring scientific testing, analysis and evaluation of one's cultural and environmental factors relating to medication treatment risk associated with adverse cultural environment, economic and community living conditions for the purpose of drug development by others, namely, data-driven analytics and reporting to developers of drugs; scientific and technological services in the field of pharmaceuticals featuring scientific testing, analysis and evaluation one's cultural and environmental factors relating to medication treatment risk associated with adverse cultural environment, economic and community living conditions for the purpose of improving quality in the field of healthcare services, specifically for improving the monitoring and diagnostics of quantitative patient drug exposure, the monitoring and diagnostics of patient drug compliance, and the data-driven analytics and reporting to providers of healthcare services in the field of pharmacovigilance activities, drug dosage recommendations, initial drug prescribing, and drug switching; scientific and technological services in the field of pharmaceuticals featuring pharmacogenomic testing, analysis, and evaluation of one's cultural and environmental factors relating to medication treatment risk associated with adverse cultural environment, economic and community living conditions for the purpose of analyzing how an individual's cultural and environmental factors affect their response to drugs, and for the purposes of improving drug selection and dosage recommendations, selecting initial and subsequent medications, identifying drug-drug interactions, avoiding adverse drug reactions, developing clinical treatment decision support recommendations, and supporting other medical diagnostic products and prescription drugs switching; scientific and technological services, namely, scientific testing, evaluation, and analysis in the field of pharmaceuticals to determine a patient's medication and drug response associated with environmental factors, sociological factors, age, biological sex, ethnicity, and other non-genetic factors to predict pharmacological drug efficacy and adverse drug reaction phenotypes for patients; scientific and technological services, namely, scientific testing, evaluation, and analysis in the field of pharmaceuticals to determine a patient's medication and drug response associated with environmental factors, sociological factors, age, biological sex, ethnicity, and other non-genetic factors, together with genetic variants, epigenetic factors and multiomics to predict pharmacological drug efficacy and adverse drug reaction phenotypes for patients; scientific and technological services in the field of pharmaceuticals featuring scientific testing, analysis and evaluation of one's cultural and environmental factors relating to medication treatment risk associated with adverse cultural environment, economic and community living conditions for the purpose of supporting drug clinical trials and research into the field of new drug development and drug repurposing; scientific and technological services in the field of pharmaceuticals featuring scientific testing, analysis and evaluation of one's cultural and environmental factors relating to medication treatment risk associated with adverse cultural environment, economic and community living conditions, including stress resulting from adverse conditions, age-related health, isolation or cognitive circumstances, behavior harmful to self or others, childhood and adolescent neglect and abuse, adult trauma associated with events, including sexual, physical and psychological abuse, acute or chronic traumatic events, including military conflict, crimes, crashes, illnesses and family deaths, stress, trauma, abuse, poverty, food insecurity and hunger, imprisonment, interpersonal conflict, violence, presence or absence of parents, children, siblings, and other family members and acquaintances, gender, ancestry, transgenerational social factors, age, income, marital status, education level, language, other household data, cultural situations, circadian data, ethnicity-related health, community living conditions, biological sex, ethnicity, and other non-genetic factors; scientific and technological services in the field of pharmaceuticals featuring scientific testing, analysis and evaluation to determine a patient's medication and drug response associated with cultural and environmental factors, including stress resulting from adverse conditions, age-related health, isolation or cognitive circumstances, behavior harmful to self or others, childhood and adolescent neglect and abuse, adult trauma associated with events, including sexual, physical and psychological abuse, acute or chronic traumatic events, including military conflict, crimes, crashes, illnesses and family deaths, stress, trauma, abuse, poverty, food insecurity and hunger, imprisonment, interpersonal conflict, violence, presence or absence of parents, children, siblings, and other family members and acquaintances, gender, ancestry, transgenerational social factors, age, income, marital status, education level, language, other household data, cultural situations, circadian data, ethnicity-related health, community living conditions, biological sex, ethnicity, and other non-genetic factors; scientific and technological services in the field of pharmaceuticals featuring scientific testing, analysis and evaluation of one's periodic changes in response to medical treatment, pharmacological adverse reactions, drug-drug interactions, drug dosing changes, and new or recurring comorbidities | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 22, 2026 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jun 22, 2026 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Nov 7, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 7, 2025 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Nov 5, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 4, 2025 | EXT5 | SOU EXTENSION 5 FILED | — |
| Apr 25, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 24, 2025 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Apr 24, 2025 | EXT4 | SOU EXTENSION 4 FILED | — |
| Apr 24, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 2, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 2, 2025 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jan 2, 2025 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Nov 14, 2024 | EXT3 | SOU EXTENSION 3 FILED | — |
| Nov 14, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 18, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 18, 2024 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Apr 18, 2024 | EXT2 | SOU EXTENSION 2 FILED | — |
| Apr 18, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 1, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 30, 2023 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Oct 30, 2023 | EXT1 | SOU EXTENSION 1 FILED | — |
| Oct 30, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 16, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Mar 21, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 21, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 1, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 10, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 9, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 9, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 9, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 11, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 11, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 11, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 15, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 15, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 14, 2022 | NWAP | NEW APPLICATION ENTERED | — |